NWRD09 for HPV-16 Related Intraepithelial Neoplasia and Cervical Cancer

This study tests NWRD09, an investigational therapeutic vaccine designed to target HPV-16 (human papillomavirus type 16) — the strain responsible for most HPV-related cancers. It is being tested in women with HPV-16-associated precancerous or cancerous cervical, vaginal, or vulvar lesions. **You may be eligible if...** - You are a woman aged 18–60 - You tested positive for HPV-16 - You have a confirmed diagnosis of HPV-16-associated precancerous or cancerous lesions of the cervix, vagina, or vulva - For precancerous (LSIL) lesions: you must have had persistent HPV-16 infection **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have a weakened immune system or are on immunosuppressive therapy - You have received prior HPV vaccines - You have active, serious infections Talk to your doctor to see if this trial is right for you.